The potential DNA methylation markers of cardiovascular disease in patients with type 2 diabetes

Yunbiao He[1†], Xia Chen[1†], Mingliang Liu[1†], Lei Zuo[1], Zhiyu Zhai[1], Long Zhou[1], Guangzhen Li[1], Li Chen[2], Guolong Qi[1,4*], Chunxia Jing[1,3,4*] and Guang Hao[1,3*]

Abstract

Background   DNA methylation is associated with cardiovascular (CV) disease. However, in type 2 diabetes (T2D) patients, the role of gene methylation in the development of CV disease is under-studied. We aimed to identify the CV disease-related DNA methylation loci in patients with T2D and to explore the potential pathways underlying the development of CV disease using a two-stage design.

Methods   The participants were from the Jinan Diabetes Cohort Study (JNDCS), an ongoing longitudinal study designed to evaluate the development of CV risk in patients with T2D. In the discovery cohort, 10 diabetic patients with CV events at baseline were randomly selected as the case group, and another 10 diabetic patients without CV events were matched for sex, age, smoking status, and body mass index as the control group. In 1438 T2D patients without CV disease at baseline, 210 patients with CV events were identified after a mean 6.5-year follow-up. Of whom, 100 patients who experienced CV events during the follow-up were randomly selected as cases, and 100 patients who did not have CV events were randomly selected as the control group in the validation cohort. Reduced representation bisulfite sequencing and Targeted Bisulfite Sequencing were used to measure the methylation profiles in the discovery and validation cohort, respectively.

Results   In the discover cohort, 127 DMRs related to CV disease were identified in T2D patients. Further, we validated 23 DMRs mapped to 25 genes, of them, 4 genes (*ARSG, PNPLA6, NEFL*, and *CRYGEP*) for the first time were reported. There was evidence that the addition of DNA methylation data improved the prediction performance of CV disease in T2D patients. Pathway analysis identified some significant signaling pathways involved in CV comorbidities, T2D, and inflammation.

[†]Yunbiao He, Xia Chen, Mingliang Liu contributed equally to this work.

*Correspondence:
Guolong Qi
qijacky1976@hotmail.com
Chunxia Jing
jcxphd@gmail.com
Guang Hao
haoguang2015@hotmail.com

Full list of author information is available at the end of the article

Conclusions In this study, we identified 23 DMRs mapped to 25 genes associated with CV disease in T2D patients, of them, 4 DMRs for the first time were reported. DNA methylation testing may help identify a high CV-risk population in T2D patients.

Keywords Type 2 diabetes, Cardiovascular disease, Methylation, Biomarker, The Han Chinese

Introduction

Cardiovascular (CV) disease, accounting for 52% of deaths, is the main cause of death in patients with type 2 diabetes (T2D). [1] People with T2D are two to six times more likely to die from CV disease than those without T2D. [2, 3] Long-term hyperglycemia is strongly associated with macrovascular complications and microvascular complications (such as kidney diseases, retinopathy, and nervous system diseases). [4] In severe cases, hyperglycemia can even lead to blindness, renal failure, deterioration of life quality, and even death. [5] Even after glycemic control is achieved, patients with T2D continue to increase inflammation and vascular problems. [6]

Burgeoning evidence suggests that epigenetic modifications may significantly derail transcriptional programs implicated in angiogenesis, oxidative stress and inflammation. [7] DNA methylation is a major epigenetic modification involving the addition of a methyl group to the 5 position of cytosine by DNA methyltransferase to form 5-methylcytosines. [8] There is increasing evidence that DNA methylation plays a vital role in the development of CV events. [9, 10]. For example, in a European prospective cohort study, it was reported that the methylation level of the *ABCG1* gene was positively correlated with the risk of CV disease. [11] Carraro et al. found that there was a significant correlation between the high methylation level of the *SERPINE1* gene and several cardiac metabolic indexes (waist circumference, waist-hip ratio, and uric acid). [12] Aberrant DNA methylation represents one of key determinants of vascular lesions and, thus, putative useful biomarkers for prevention and diagnosis of CV risk in diabetics. [13] In a recent pilot study, Benincasa et al. reported that *SPARC* hypomethylation in CD08+T cells may be a useful biomarker of vascular complications in pre-diabetics patients. [14] However, the role of gene methylation in the development of CV disease need to be further investigated.

Growing evidence has demonstrated that network medicine is a promising molecular-bioinformatic approach to identify the signaling pathways underlying the pathogenesis of CV disease in patients with T2D. [13, 15, 16] The purpose of this study was to identify the CV disease-related DNA methylation loci in patients with T2D and to explore the potential pathways underlying the development of CV disease using network approaches.

Methods

Study subjects

The participants were from the Jinan Diabetes Cohort Study (JNDCS), an ongoing longitudinal study designed to evaluate the development of CV risk in patients with T2D. A total of 2756 patients were continuously recruited between 2012 and 2017 from the First Affiliated Hospital of Jinan University, Guangzhou, China. All patients were diagnosed according to the 2003 American Diabetes Association [17].

Demographic information was collected by standardized questionnaire, and physical measurements and laboratory test results were extracted from the hospital medical record system. The venous blood (5 mL) was drawn in the morning and stored at -70 ℃. All patients were followed up by telephone calls in 2021, to collect information on CV events, including coronary artery disease, myocardial infarction, percutaneous coronary angioplasty and/or stenting, coronary artery bypass grafting, heart failure, and CV death.

The study was approved by the Institutional Review Board of Jinan University, and all participants provided written informed consent.

Study design

The prevalence of CV disease was 50% (1378/2756) at baseline. In the discovery cohort, 10 diabetic patients with CV events were randomly selected as the case group, and another 10 diabetic patients without CV events were matched for sex, age ($\pm$1 years), smoking status, and body mass index ($\pm$0.5 kg/m^2) as the control group. Reduced representation bisulfite sequencing (RRBS) was used to measure the methylation profiles. The selection principle of methylated fragments for validation were as follows: (1) The results of GO enrichment and KEGG enrichment [18]; (2) Literature review; (3) Significantly different methylation sites. The details were provided **in Supplementary File 1.** (**Figure S1-S2 and Table S1-S3**)

In 1438 T2D patients without CV disease at baseline, 210 patients with CV events were identified after a mean 6.5-year follow-up. Of whom, 100 patients who experienced CV events during the follow-up were randomly selected as cases, and 100 patients who did not have CV events were randomly selected as the control group (a nested case-control design) in the validation cohort. (**Figure S3 in Supplementary File 1**)

Reduced representation bisulfite sequencing (RRBS)

Genomic DNA was extracted from peripheral whole blood using DNeasy Blood & Tissue Kit (Qiagen). RRBS library was prepared using the Acegen Rapid RRBS Library Prep Kit (Acegen, Cat. No. AG0422). In brief, 100 ng of genomic DNA was digested with MspI, end-repaired, 3'-dA-tailed, and ligated to 5-methylcytosine-modified adapters. After bisulfite treatment, the DNA was amplified with 12 cycles of PCR using Illumina 8-bp dual index primers. Size selection was performed to obtain DNA fractions of MspI-digested products in the range of 100–350 bp using a dual-SPRI® protocol according to the manufacturer's protocol. The constructed RRBS libraries were then analyzed by Agilent 2100 Bioanalyzer and finally sequenced on Illumina platforms using a 150×2 paired-end sequencing protocol. [19–21].

Targeted Bisulfite sequencing (TBS)

We used trimming to truncate the sequencing adapters and low-quality data of the sequencing data and obtain clean data for subsequent analysis. Trimmomatic (version 0.36) software was used for raw data trimming. Using the sliding window method, 4 bases are a window. If the average base quality value of the window is lower than 15, the reads will be truncated there. Next, the clean data was aligned with the amplified target sequence, and the BSMAP 2.73 software was used for alignment. The alignment mode was mapped to 2 forward strands, i.e. BSW (++) and BSC (-+). After the alignment was completed, the methylation level of the CG site was calculated using the python program for calculating methylation that comes with BSMAP. The calculation principle is Methyl value = C-reads / (C-reads + T-reads) * 100%, where C-reads is the number of methylation-supporting reads covering the site (the site is measured as C reads), T-reads is the number of reads that do not support methylation covering the site (reads with a T at the site). [22, 23].

Statistical analysis

Continuous variables were expressed as means ± standard deviation, and the mean values of the two groups are compared by student's *t*-test. Categorical variables were reported as percentages (n [%]), and the χ^2 test was used to test differences between groups. The DNA methylation rates in DMRs and CpG sites between the two groups were compared by student's *t*-test, and an FDR < 0.05 was considered validated successfully. Moreover, random forests were used to evaluate the variable importance of CV risk factors. The area under the receiver operating characteristic curve (AUC) was estimated to assess the potential predictive value of DNA methylation data.

R (version 4.0.5) package "org.Hs.eg.db" (version 3.12.0) and "clusterProfiler" (version 4.4.4) were used for GO-BP

biological process analysis, GO-MF molecular function analysis, GO-CC cytological component analysis, and KEGG signaling pathway analysis [18]. In the process of GO enrichment analysis, functional items were selected from the results of GO enrichment and plotted according to the value of *P* < 0.05. In the process of KEGG enrichment analysis, the parameter was set as *P* < 0.05. We also performed Protein-protein interaction (PPI) Network analysis for DMR along the sequencing direction of RRBS and TBS, respectively. String [24] (https://string-db.org/) is one of the databases of protein-protein interaction networks that enables the analysis of known proteins and the prediction of proteins with possible biological effects. The connection between the protein network was set as reliability, and the minimum action score was set as 0.400. The isolated or scattered nodes were removed before retrieval analysis and graph drawing. Further, we utilized a network visualization tool 'Cytoscape' [25] for the visualization of the network where nodes denote proteins and edges denote the connections between the nodes, and the genes we uploaded were filled in yellow.

All analyses were performed using Stata software version 12 (STATA Corp., TX, US) and R 4.0.5 (R Foundation for Statistical Computing Vienna, Austria).

Result

Characteristics of study participants

The basic characteristics and laboratory examination indices for the discovery and validation cohort were presented in Table 1. There are no statistical differences between the case and control groups in the discovery cohort. For the validation cohort, there was a statistical difference in educational attainment, urine protein, and carotid atherosclerosis (*P* < 0.05).

RRBS in the discovery cohort

Using the next generation RRBS, a total of 20,259 DMRs were measured, of them, 12,981 DMRs were significantly different between T2D patients with and without CV disease (FDR < 0.01) (6382 decreased, 6599 increased; **Table S4 in Supplementary File 2**). (Fig. 1A). There were 57.19% of the methylation sites located in the gene body and 22.57% located in the promoter (Fig. 1B **and Table S6 in Supplementary File 2**). According to the results from GO enrichment, KEGG enrichment, and literature review, we initially selected 127 DMRs for further validation (**Supplementary File 2 for more details**). (**Table S7 in Supplementary File 2**).

TBS in the validation cohort

Of 127 DMRs, the bisulfite sequencing primers in 87 DMRs were successfully designed for TBS analysis. A total of 23 DMRs with 25 genes were further validated (Fig. 2**and Table S7-9 in Supplementary File 2**). Twelve

Table 1 Baseline characteristics of the study population

Characteristics	RRBS			TBS		
	Controls (n = 10)	Cases (n = 10)	*P*-value	Controls (n = 100)	Cases (n = 100)	*P*-value
Gender, n (%)			1.000			1.000
Male	3 (30.00)	3 (30.00)		39 (39.00)	39 (39.00)	
Female	7 (70.00)	7 (70.00)		61 (61.00)	61 (61.00)	
Age (years)	59.50 ± 10.63	59.50 ± 10.63	1.000	64.79 ± 10.74	64.78 ± 10.77	0.995
Married, n (%)	10 (100.00)	10 (100.00)		95 (95.00)	97 (97.00)	0.470
Education attainment, n (%)			0.645			**0.005**
Less than primary school	4 (40.00)	3 (30.00)		55 (55.00)	43 (43.00)	
Middle school	4 (40.00)	6 (60.00)		20 (20.00)	41 (41.00)	
Tertiary school or higher	2 (20.00)	1 (10.00)		25 (25.00)	16 (16.00)	
Occupation, n (%)			0.121			0.201
Retiree	1 (10.00)	4 (40.00)		50 (50.00)	59 (59.00)	
Others	9 (90.00)	6 (60.00)		50 (50.00)	41 (41.00)	
Body mass index (kg/m2)	25.33 ± 3.38	25.76 ± 3.91	0.793	24.09 ± 3.03	25.03 ± 3.86	0.057
Smokers, n (%)	0 (0.00)	0 (0.00)		16 (16.00)	26 (26.00)	0.083
Drinkers, n (%)	0 (0.00)	0 (0.00)		5 (5.00)	8 (8.00)	0.390
Laboratory results						
Fast blood-glucose (mmol/L)	9.03 ± 3.15	8.57 ± 3.04	0.743	9.86 ± 4.66	8.69 ± 4.69	0.101
Postprandial blood glucose (mmol/L)	17.16 ± 4.73	15.13 ± 3.95	0.310	15.57 ± 5.86	14.51 ± 5.77	0.228
HbA1c (%)	8.77 ± 2.92	8.65 ± 2.25	0.929	9.12 ± 2.74	8.71 ± 2.67	0.309
Fasting C-peptide (ng/ml)	1.52 ± 0.84	1.74 ± 1.14	0.733	1.67 ± 1.50	1.80 ± 1.51	0.605
1 h postprandial, C-peptide (ng/ml)	4.57 ± 4.00	4.75 ± 4.91	0.960	3.38 ± 2.82	3.44 ± 2.82	0.921
2 h postprandial, C-peptide (ng/ml)	3.16 ± 1.82	6.21 ± 7.34	0.308	4.15 ± 3.40	4.71 ± 3.77	0.330
Urinary creatinine (μmol/L)	10712.75 ± 6879.51	6726.25 ± 4451.13	0.190	7408.81 ± 4108.92	7770.75 ± 4797.89	0.619
Urinary microalbumin (μg/mL)	152.25 ± 382.83	136.05 ± 331.71	0.929	198.42 ± 697.97	64.01 ± 152.52	0.095
Urinary protein (g/L)				2.92 ± 3.49	0.21 ± 0.12	**0.025**
GFR (ml/min)	86.70 ± 24.97	62.86 ± 19.38	0.091	73.81 ± 18.67	75.00 ± 16.43	0.721
TC (mmol/L)	4.95 ± 1.40	5.02 ± 0.99	0.906	5.03 ± 1.35	4.93 ± 1.11	0.576
TG (mmol/L)	2.54 ± 1.72	1.41 ± 0.53	0.062	1.92 ± 1.81	1.94 ± 1.27	0.939
HDL (mmol/L)	1.11 ± 0.20	1.10 ± 0.21	0.914	1.12 ± 0.27	1.10 ± 0.29	0.587
LDL (mmol/L)	2.48 ± 0.87	3.12 ± 0.73	0.091	2.97 ± 1.02	2.93 ± 0.97	0.784
ALT (U/L)	25.70 ± 8.57	21.70 ± 10.57	0.365	29.73 ± 28.43	37.33 ± 102.37	0.490
Blood creatinine (μmol/L)	63.30 ± 11.75	61.30 ± 11.03	0.699	75.11 ± 47.57	73.48 ± 39.31	0.794
Blood uric acid (μmol/L)	364.3 ± 135.95	337.7 ± 72.23	0.592	372.09 ± 119.21	373.12 ± 122.23	0.953
hsCRP (mg/L)	4.45 ± 1.76	5.93 ± 5.19	0.734	7.95 ± 14.37	24.94 ± 59.14	0.221
Comorbidities						
Hypertension, n (%)	5 (50.00)	6 (66.67)	0.463	60 (60.00)	67 (67.00)	0.304
Hyperlipemia, n (%)	2 (20.00)	5 (50.00)	0.160	36 (36.00)	39 (39.00)	0.661
Carotid atherosclerosis, n (%)	9 (90.00)	10 (100.00)		66 (70.21)	84 (91.30)	**< 0.001**
Reduced left ventricular diastolic function, n (%)	6 (66.67)	7 (87.50)	0.312	62 (70.45)	67 (81.71)	0.087
Peripheral neuropathy, n (%)	2 (25.00)	2 (28.57)	0.876	10 (14.93)	14 (28.00)	0.083

Continuous variables are presented as mean ± standard deviation, and categorical variables are presented as cases (percentage)

Abbreviation: HbA1c: glycated hemoglobin |glycosylated hemoglobin; GFR: Glomerular filtration rate; TC: total cholesterol; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; ALT: Alanine aminotransferase; hs-CRP: hypersensitive C-reactive protein

genes were hypermethylated (*LMF1, FZD5, COL6A1, TBX1, CACNA1D, PTPRN2, NEFL, RXRA, G6PD, IKBKG, ADCY6* and *WNT7A* genes), and 13 genes were hypomethylation (*PIK3CD, PDE4DIPP1, H19, MIR675, ARSG, PNPLA6, CRYGEP, TNIP1, PON1, COL5A1, KDM6A, CREB5* and *SERPINE1*). Of them, 4 genes (*ARSG, PNPLA6, NEFL,* and *CRYGEP*) were reported for the first time. (**Table S9 in Supplementary File 2**)

Predictive value of the identified methylation sites
A total of 32 potential variables in Table 1 were analyzed by random forest, of them, 9 variables (postprandial blood glucose, smoking status, peripheral neuropathy,

Fig. 1 The distribution of differentially methylated sites (DMRs) using reduced representation bisulfite sequencing (RRBS) in the discovery cohort **A**: The heatmap of DMRs **B**: The location of DMRS position

fast blood-glucose, carotid atherosclerosis, occupation, education attainment, high sensitivity c-reactive protein (hsCRP), and hypertension) with Mean Decrease Accuracy value>0.5 were included in the prediction model, and the AUC was 69.2% (Fig. 3). When further adding the DMRs with the top 4 importance ranking (including DMR for *LMF1* and *SOX8*, DMR for *TNIP1*, and DMR for *FZD5*) to the model, the prediction performance of the model was improved substantially, and its AUC reached 88.6% (Fig. 4). Further, when the top four methylation sites (including methylation sites of *MIR675*, *ARSG*, *TNIP1*, and *KDM6A*) were added to the model, the prediction performance of the model was significantly improved (AUC=94.2%). (Fig. 5)

Pathway analysis and GO enrichment analysis
The genes corresponding to the validated DMRs were analyzed by GO and KEGG enrichment, and yielded significant (FDR<0.05) enrichment of 22 KEGG and 17 GO pathways (Fig. 6, **Table S10 and S11 in Supplementary File 2**). These pathways are involved in CV comorbidities (such as Type II diabetes mellitus, Alzheimer's disease, Cushing syndrome, and Dilated cardiomyopathy), cancers (such as gastric cancer, breast cancer, hepatocellular carcinoma), and the inflammatory pathway (such as signaling pathways regulating pluripotency of stem cells, mTOR signaling pathway, hippo signaling pathway, pi3k-Akt signaling pathway, and cAMP signaling pathway). Further, there were 25 genes located in the 23 DMRs used for PPI enrichment analysis. (**Table S9 in Supplementary File 2**). The proteins in this network were related to some

signaling pathways, such as mTOR signaling pathway, cellular senescence, hippo signaling pathway, and type 2 diabetes mellitus. (Fig. 7)

Discussion
DNA methylation plays a critical role in the development of CV disease. It is well-known that patients with T2D are at higher risk for CV disease than those without, but the role of DNA methylation in T2D patients with CV is under-studied. In this study, we identified 23 DMRs mapped to 25 genes associated with CV disease in T2D patients, of them, 4 genes (*ARSG*, *PNPLA6*, *NEFL*, and *CRYGEP*) for the first time were reported. DNA methylation testing may help identify a high CV-risk population in T2D patients.

Most identified genes in our study were associated with CV disease and T2D. Studies have shown that the *LMF1* gene is involved in the regulation of lipase activity and metformin increased *LMF1* expression in the heart, suggesting that stimulation of *LMF1* may play a part in its TG-lowering action. [26, 27] Consistently, we found that the methylation level of the *LMF1* gene promoter significantly increased in T2D patients with CV disease. It is reported that SOX8 proteins were markedly increased in patients with heart failure. [28] In line with our results, *SOX8* gene body methylation was hypermethylated. The methylation of the *FZD5* gene promoter was increased in T2D patients with CV disease, which corroborates the findings of another study showing the involvement of *FZD5* in regulating diabetic vasculopathy. [29] Gene polymorphism of *TNIP1* was associated with coronary

Fig. 2 A total of 23 validated differentially methylated sites (DMRs) **A**: 23 DMR in the discovery cohort **B**: 23 DMR in the validation cohort

heart disease in the Chinese Han population, [30] and we observed a decrease in *TNIP1* gene body methylation in T2D patients with CV disease. The methylation levels of *NEFL* gene promoter in T2D patient with CV disease was elevated. Similarly, the study by Yadi et al. showed that the *NEFL* gene is involved in the process of the protective effect of cardiac insufficiency. [31] However, the relationship between NEFL and CV disease is still unclear and further studies are needed.

We, for the first time, identified 4 novel DMRs with 4 genes (*ARSG, PNPLA6, NEFL,* and *CRYGEP*) in T2D patients. Inflammation plays a critical role in the genesis, progression, and the manifestation of CV disease. [32, 33] NEFL (neurofilament light chain) is a neuronal cytoplasmic protein highly expressed in large calibre myelinated axons. [34] NEFL is considered as a potential biomarker for diverse neurological diseases, such as Alzheimer's disease and frontotemporal dementia. [35, 36] NEFL was reported to activate the mTOR signaling

Fig. 3 The baseline predictive model using the top 9 ranked important variables **A**: The importance ranking of selected variables using random forest **B**: ROC curves of the predictive model with top 9 ranked important variables (postprandial blood glucose, smoking status, peripheral neuropathy, fast blood-glucose, carotid atherosclerosis, occupation, education attainment, high sensitivity c-reactive protein, and hypertension)


Fig. 4 The predictive model plus using the top 9 ranked important variables and top 4 ranked important DMRs **A**: The importance ranking of significant DMRs using random forest **B**: ROC curves of the predictive model using the top 9 ranked important variables (postprandial blood glucose, smoking status, peripheral neuropathy, fast blood-glucose, carotid atherosclerosis, occupation, education attainment, high sensitivity c-reactive protein, and hypertension) plus top 4 ranked important DMRs (DMR025, DMR061, DMR040, and DMR074)

pathway. [34, 37] Many studies showed that mammalian target of rapamycin (mTOR) signaling plays an important role in the general and inflammation-driven mechanisms that are related to the CV disease. [38, 39] The *CRYGEP* gene is considered to be a pseudogene with no evidence of expression in humans. Nevertheless, the gene remains largely intact and is at least potentially involved in gene conversion and even reactivation of the active gene. [40] It was suggested that the *CRYGEP* gene methylation level may affect the magnitude of Bacillus Calmette–Guérin immune responses. [41] Patatin-like phospholipase domain-containing protein 6 (PNPLA6) belongs to a family of hydrolases with at least eight members in mammals that react with different substrates such as phospholipids, triacylglycerols, and retinol esters. [42] PNPLA6 preferably hydrolyzes phosphatidylcholine (PC) and lysophosphatidylcholine (LPC). [43] LPC could be a messenger by signaling through membrane receptors. It was expected that PNPLA6 contains domains that are predicted to bind cAMP, [44] and the cAMP signaling

Fig. 5 The predictive model plus using the top 9 ranked important variables and top 4 ranked important CpGs **A**: The importance ranking of significant DMRs using random forest **B**: ROC curves of the predictive model using the top 9 ranked important variables (postprandial blood glucose, smoking status, peripheral neuropathy, fast blood-glucose, carotid atherosclerosis, occupation, education attainment, high sensitivity c-reactive protein, and hypertension) plus top 4 ranked important CpGs located in DMR012, DMR026, DMR061, and DMR089


Fig. 6 Pathway enrichment map of validated methylation sites **A**: Scatter plot of GO enrichment analysis **B**: Scatter plot of KEGG enrichment analysis

pathway plays a key role in the regulation of cardiac function. [45] Consistently, our pathway analyses also yielded significant enrichment in the mTOR signaling pathway and cAMP signaling pathway. These genes have not been well-studied but the results provide some clues for future research directions.

This is among the first study to investigate the role of DNA methylation in T2D patients with CV disease. One strength is that a nested case-control design was used in the validation cohort. Another strength is that taking advantage of RRBS, we specifically analyzed DMRs rather than the methylation level of single CpG dinucleotides. DMRs can control spatiotemporal gene expression, have the most statistical power and by-pass putative effects

of genetic polymorphisms during epigenome-wide association studies. [14] However, this study has some limitations. First, different tests are used in the discovery and validation phases, and not all bisulfite sequencing primers of identified DMRs were successfully designed for validation, which may miss new sites. Second, the lifestyles of T2D patients may have changed after diagnosis. Third, the patients in this study come from the Han nationality in southern China, so extrapolating the results to other populations should be cautious. Fourth, this study is limited by a small sample size, so future studies will benefit from the confirmation of these results in larger sample sizes. Finally, blood-based methylation signatures should be validated in cardiac tissues to advance our knowledge

Fig. 7 Schematic representation of spatial and planar interactions of proteins expressed by genes **A**: Spatial structure diagram of the gene-expressed proteins **B**: Planar structure diagram of the gene-expression

about the progression of CV diseases in patients with T2D.

Conclusion

In this study, we validated 19 DMRs mapped to 21 genes associated with CV disease in T2D patients, moreover, we identified 4 novel DMRs with 4 genes (*ARSG, PNPLA6, NEFL,* and *CRYGEP*). Consistently, Pathway analyses also found that the related pathways are involved in CV comorbidities, T2D, and inflammation. The differentially methylated genes identified in this study may be valuable biomarkers for the early detection of CV disease and may help improve treatment strategies, drug targets, and diagnostic activities to reduce the threat to human health from CV disease in T2D. More independent cohort studies are required to confirm the prediction value of the DNA methylation data for the high CV-risk population in T2D patients.

Abbreviations
CV   cardiovascular
T2D   type 2 diabetes
RRBS   reduced representation bisulfite sequencing
TBS   Targeted Bisulfite Sequencing

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12920-023-01689-3.

Supplementary Material 1

Supplementary Material 2

Declarations

Competing interests
The authors declare no competing interests.

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Jinan University, and was conducted according to the guidelines of the Declaration of Helsinki. All participants provided informed consent to participate. All methods in this study were performed in accordance with the relevant guidelines and regulations.

Consent for publication
Not Applicable.

Author details
[1]Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, 601 West Huangpu Road, Guangzhou 510632, Guangdong, China [2]Department of Medicine, Medical College of Georgia, Georgia Prevention Institute, Augusta University, Augusta, GA, USA [3]Guangdong Key Laboratory of Environmental Exposure and Health, Jinan University, Guangzhou, China [4]Department of Epidemiology, School of Medicine, Jinan University, 601 West Huangpu Road, Guangzhou 510632, Guangdong, China

He *et al. BMC Medical Genomics*   (2023) 16:242

Page 10 of 11

References

1. Morrish N, Wang S-L, Stevens L, Fuller J, Keen H. Mortality and causes of death in the WHO multinational study of Vascular Disease in Diabetes. Diabetologia. 2001;44(2):14–S21.
2. Gæde P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241(19):2035–8.
4. Azcutia V, Abu-Taha M, Romacho T, Vázquez-Bella M, Matesanz N, Luscinskas FW, Rodríguez-Mañas L, Sanz MJ, Sánchez-Ferrer CF, Peiró C. Inflammation determines the pro-adhesive properties of high extracellular d-glucose in human endothelial cells in vitro and rat microvessels in vivo. PLoS ONE. 2010;5(4):e10091.
5. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes Mellitus. Endocr Rev. 2016;37(3):278–316.
6. Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A. The metabolic memory theory and the early treatment of hyperglycemia in Prevention of Diabetic Complications. Nutrients 2017, 9(5).
7. Costantino S, Ambrosini S, Paneni F. The epigenetic landscape in the cardiovascular complications of diabetes. J Endocrinol Invest. 2019;42(5):505–11.
8. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123(19):2145–56.
9. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436–43.
10. Paneni F, Volpe M, Lüscher TF, Cosentino F. SIRT1, p66(shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes. 2013;62(6):1800–7.
11. Cardona A, Day FR, Perry JRB, Loh M, Chu AY, Lehne B, Paul DS, Lotta LA, Stewart ID, Kerrison ND, et al. Epigenome-Wide Association study of Incident Type 2 diabetes in a british Population: EPIC-Norfolk Study. Diabetes. 2019;68(12):2315–26.
12. Carraro JC, Mansego ML, Milagro FI, Chaves LO, Vidigal FC, Bressan J, Martínez JA. LINE-1 and inflammatory gene methylation levels are early biomarkers of metabolic changes: association with adiposity. Biomarkers. 2016;21(7):625–32.
13. Napoli C, Benincasa G, Schiano C, Salvatore M. Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):239–47.
14. Benincasa G, Franzese M, Schiano C, Marfella R, Miceli M, Infante T, Sardu C, Zanfardino M, Affinito O, Mansueto G, et al. DNA methylation profiling of CD04(+)/CD08(+) T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study. Ann Med Surg (Lond). 2020;60:218–26.
15. Benincasa G, Marfella R, Della Mura N, Schiano C, Napoli C. Strengths and Opportunities of Network Medicine in Cardiovascular Diseases. Circ J. 2020;84(2):144–52.
16. Silverman EK, Schmidt H, Anastasiadou E, Altucci L, Angelini M, Badimon L, Balligand JL, Benincasa G, Capasso G, Conte F, et al. Molecular networks in Network Medicine: Development and applications. Wiley Interdiscip Rev Syst Biol Med. 2020;12(6):e1489.
17. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7.
18. Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.
19. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20.
20. Jühling F, Kretzmer H, Bernhart SH, Otto C, Stadler PF, Hoffmann S. Metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data. Genome Res. 2016;26(2):256–62.
21. Xi Y, Li W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinformatics. 2009;10:232.
22. Pan X, Gong D, Nguyen DN, Zhang X, Hu Q, Lu H, Fredholm M, Sangild PT, Gao F. Early microbial colonization affects DNA methylation of genes related to intestinal immunity and metabolism in preterm pigs. DNA Res. 2018;25(3):287–96.
23. Gao F, Liang H, Lu H, Wang J, Xia M, Yuan Z, Yao Y, Wang T, Tan X, Laurence A, et al. Global analysis of DNA methylation in hepatocellular carcinoma by a liquid hybridization capture-based bisulfite sequencing approach. Clin Epigenetics. 2015;7(1):86.
24. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–d368.
25. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
26. Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455.
27. Forcheron F, Basset A, Del Carmine P, Beylot M. Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate. Diabetes Metab. 2009;35(6):452–7.
28. Liu CF, Ni Y, Thachil V, Morley M, Moravec CS, Tang WHW. Differential expression of members of SOX family of transcription factors in failing human hearts. Transl Res. 2022;242:66–78.
29. Dai Y, Lu H, Wang S, Chang S, Li C, Huang Z, Zhang F, Yang H, Shen Y, Chen Z et al. MicroRNA-216b actively modulates diabetic angiopathy through inverse regulation on FZD5. *Gene* 2018, 658:129–135.
30. Song Y, Yan M, Li J, Li J, Jin T, Chen C. Association between TNIP1, MPHOSPH6 and ZNF208 genetic polymorphisms and the coronary artery disease risk in chinese Han population. Oncotarget. 2017;8(44):77233–40.
31. Liu Y, Lai G, Guo Y, Tang X, Shuai O, Xie Y, Wu Q, Chen D, Yuan X. Protective effect of Ganoderma lucidum spore extract in trimethylamine-N-oxide-induced cardiac dysfunction in rats. J Food Sci. 2021;86(2):546–62.
32. Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, Jones SR, Toth PP. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130.
33. Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022;108(1):73–9.
34. Zhang H, Wang D, Tong J, Fang J, Lin Z. MiR-30b-5p attenuates the inflammatory response and facilitates the functional recovery of spinal cord injury by targeting the NEFL/mTOR pathway. Brain Behav 2022:e2788.
35. Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano MA, Heslegrave AJ, Zetterberg H, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93(6):651–8.
36. Shahid SS, Wen Q, Risacher SL, Farlow MR, Unverzagt FW, Apostolova LG, Foroud TM, Zetterberg H, Blennow K, Saykin AJ, et al. Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. Brain. 2022;145(6):2149–60.
37. Peng G, Yuan X, Yuan J, Liu Q, Dai M, Shen C, Ma J, Liao Y, Jiang W. miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL. Mol Cell Biochem. 2015;409(1–2):103–11.
38. Feng E, Wang J, Wang X, Wang Z, Chen X, Zhu X, Hou W. Inhibition of HMGB1 might enhance the Protective Effect of Taxifolin in Cardiomyocytes via PI3K/AKT signaling pathway. Iran J Pharm Res. 2021;20(2):316–32.
39. Kaldirim M, Lang A, Pfeiler S, Fiegenbaum P, Kelm M, Bonner F, Gerdes N. Modulation of mTOR Signaling in Cardiovascular Disease to Target Acute and chronic inflammation. Front Cardiovasc Med. 2022;9:907348.
40. Wistow G. The human crystallin gene families. Hum Genomics. 2012;6(1):26.
41. Hasso-Agopsowicz M, Scriba TJ, Hanekom WA, Dockrell HM, Smith SG. Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination. Sci Rep. 2018;8(1):13086.
42. Sunderhaus ER, Law AD, Kretzschmar D. Disease-Associated PNPLA6 mutations maintain partial functions when analyzed in Drosophila. Front NeuroSci 2019, 13.
43. Kmoch S, Majewski J, Ramamurthy V, Cao S, Fahiminiya S, Ren H, MacDonald IM, Lopez I, Sun V, Keser V, et al. Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness. Nat Commun. 2015;6:5614.

44. Bettencourt da Cruz A, Wentzell J, Kretzschmar D. Swiss cheese, a protein involved in progressive neurodegeneration, acts as a noncanonical regulatory subunit for PKA-C3. J Neurosci. 2008;28(43):10885–92.

45. Irfan M, Kwon HW, Lee DH, Shin JH, Yuk HJ, Kim DS, Hong SB, Kim SD, Rhee MH. Ulmus parvifolia modulates platelet functions and inhibits Thrombus formation by regulating integrin αIIbβ3 and cAMP signaling. Front Pharmacol. 2020;11:698.